Eli Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly and Company filed six lawsuits on August 12, 2026, targeting U.S. businesses like Aesthetic Envy and Striker Pharmacy for selling unauthorized versions of its experimental obesity drug, retatrutide. Although retatrutide remains in Phase 3 clinical trials and lacks FDA approval, high demand has fueled a thriving black market. Lilly has referred over 200 entities to law enforcement, while U.S. Customs intercepted nearly 90,000 vials of illicit GLP-1 drugs in July 2026 alone.

Eli Lilly retatrutide lawsuits

• ▪The six companies targeted in Eli Lilly and Company's August 12, 2026 lawsuits are Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide.
• ▪Eli Lilly and Company filed six lawsuits on August 12, 2026, against U.S. companies for allegedly selling unauthorized, black-market versions of its experimental obesity drug retatrutide.
• ▪Eli Lilly and Company's lawsuits target a range of businesses including compounding pharmacies, medical spas, and online peptide vendors that market retatrutide to consumers.

Illegal retatrutide black market

• ▪Unapproved retatrutide has been sold openly in physical retail locations, including posters advertising the drug at two Brooklyn bodegas as recently as August 8, 2026.
• ▪Some online peptide vendors market retatrutide "for research use only" without a prescription, which Eli Lilly and Company alleges is actually tailored for direct consumer injection.
• ▪High demand for obesity treatments and promising clinical trial results have fueled a thriving online black market for unapproved retatrutide products on social media and websites.

Consumer safety risks

• ▪Eli Lilly and Company states that consumers experiencing adverse reactions from illicit products could associate those negative experiences with the official brand, damaging the future of retatrutide.
• ▪Eli Lilly and Company alleges that unauthorized retatrutide products sold on the black market are unverified, unapproved, and likely to contain contaminants that endanger consumer safety.

FDA regulatory violations

• ▪In June 2026, the U.S. Food and Drug Administration stated that sales of unapproved versions of GLP-1 products, including retatrutide, are illegal and cannot lawfully be compounded.
• ▪Retatrutide is currently in Phase 3 clinical trials for obesity and type 2 diabetes and has not been approved for human use by the Food and Drug Administration or any other global regulator.

U.S. Customs drug seizures

• ▪U.S. Customs and Border Protection intercepted over 690 shipments totaling more than 31,000 units of illicit GLP-1 drugs during fiscal year 2025.
• ▪Seizures of illicit GLP-1 drugs by U.S. Customs and Border Protection more than doubled in July 2026, with over 1,400 seizures and nearly 90,000 vials intercepted.

Stakeholder enforcement calls

• ▪Eli Lilly and Company referred more than 200 individuals and entities selling unauthorized retatrutide to the Food and Drug Administration, the Department of Justice, and other law enforcement agencies.
• ▪Eli Lilly and Company called on social media platforms, e-commerce sites, payment processors, credit card companies, and shipping firms to take stronger action against unauthorized retatrutide sellers.